MNTA

Momenta Pharmaceuticals Inc

A biotechnology company that developed therapies for rare, immune-mediated diseases, Momenta Pharmaceuticals was born in 2001 from an MIT professor's lab studying complex sugars. Its name comes from the Latin plural of "momentum," reflecting its drive to speed up drug discovery. Its flagship drug, nipocalimab, targets the FcRn receptor to tame harmful antibodies in autoimmune conditions, and the company was acquired by Johnson & Johnson in 2020.